Survey of U.S. Neurologists' Attitudes Towards Deep Brain Stimulation for Parkinson's Disease
Identifieur interne : 001724 ( Main/Corpus ); précédent : 001723; suivant : 001725Survey of U.S. Neurologists' Attitudes Towards Deep Brain Stimulation for Parkinson's Disease
Auteurs : Ludy C. Shih ; Daniel TarsySource :
- Neuromodulation: Technology at the Neural Interface [ 1094-7159 ] ; 2011-05.
English descriptors
- KwdEn :
Abstract
Objectives: Deep brain stimulation (DBS) for Parkinson's disease (PD) was approved by the Food and Drug Administration in 2002 and has demonstrated clinical benefit in advanced PD. Our aim was to assess attitudes of U.S. neurologists towards the role of DBS in management of advanced PD. Materials and Methods: We sent a 40‐item Internet‐based survey assessing opinions regarding the role of medical and surgical therapies in managing PD to 7722 neurologists in the American Medical Association Physician MasterFile data base. Results: The response rate was low (4.2%). In total, 78 of the 298 (26%) responders self‐identified as movement disorders specialists. Specialists and non‐specialists had differences on a number of medical strategies used to manage PD. There were no statistically significant differences in reasons for or against referring patients for DBS, except for the number of non‐specialists who agreed with referring a patient who had a “poor or absent response to levodopa” (71% vs. 16%, p < 0.001). Both groups indicated a need for more information concerning appropriate indications for DBS, adverse effects of surgery, and postoperative programming. Conclusions: Movement disorders specialists and non‐specialists were in general agreement towards the beneficial role of DBS in management of advanced PD except for whether to refer patients with poor or absent response to levodopa.
Url:
DOI: 10.1111/j.1525-1403.2011.00350.x
Links to Exploration step
ISTEX:1D9EE26C5DEE702DF5350DF8351846544D65813FLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Survey of U.S. Neurologists' Attitudes Towards Deep Brain Stimulation for Parkinson's Disease</title><author><name sortKey="Shih, Ludy C" sort="Shih, Ludy C" uniqKey="Shih L" first="Ludy C." last="Shih">Ludy C. Shih</name></author><author><name sortKey="Tarsy, Daniel" sort="Tarsy, Daniel" uniqKey="Tarsy D" first="Daniel" last="Tarsy">Daniel Tarsy</name><affiliation><mods:affiliation>Department of Neurology, National Parkinson Foundation Center of Excellence, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA, USA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:1D9EE26C5DEE702DF5350DF8351846544D65813F</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1111/j.1525-1403.2011.00350.x</idno><idno type="url">https://api.istex.fr/document/1D9EE26C5DEE702DF5350DF8351846544D65813F/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">001724</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Survey of U.S. Neurologists' Attitudes Towards Deep Brain Stimulation for Parkinson's Disease</title><author><name sortKey="Shih, Ludy C" sort="Shih, Ludy C" uniqKey="Shih L" first="Ludy C." last="Shih">Ludy C. Shih</name></author><author><name sortKey="Tarsy, Daniel" sort="Tarsy, Daniel" uniqKey="Tarsy D" first="Daniel" last="Tarsy">Daniel Tarsy</name><affiliation><mods:affiliation>Department of Neurology, National Parkinson Foundation Center of Excellence, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA, USA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Neuromodulation: Technology at the Neural Interface</title><idno type="ISSN">1094-7159</idno><idno type="eISSN">1525-1403</idno><imprint><publisher>Blackwell Publishing Inc</publisher><pubPlace>Malden, USA</pubPlace><date type="published" when="2011-05">2011-05</date><biblScope unit="volume">14</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="208">208</biblScope><biblScope unit="page" to="213">213</biblScope></imprint><idno type="ISSN">1094-7159</idno></series><idno type="istex">1D9EE26C5DEE702DF5350DF8351846544D65813F</idno><idno type="DOI">10.1111/j.1525-1403.2011.00350.x</idno><idno type="ArticleID">NER350</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1094-7159</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Deep brain stimulation</term><term>Parkinson's disease</term><term>patient selection</term><term>prospective nonrandomized study</term><term>subthalamic nucleus</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Objectives: Deep brain stimulation (DBS) for Parkinson's disease (PD) was approved by the Food and Drug Administration in 2002 and has demonstrated clinical benefit in advanced PD. Our aim was to assess attitudes of U.S. neurologists towards the role of DBS in management of advanced PD. Materials and Methods: We sent a 40‐item Internet‐based survey assessing opinions regarding the role of medical and surgical therapies in managing PD to 7722 neurologists in the American Medical Association Physician MasterFile data base. Results: The response rate was low (4.2%). In total, 78 of the 298 (26%) responders self‐identified as movement disorders specialists. Specialists and non‐specialists had differences on a number of medical strategies used to manage PD. There were no statistically significant differences in reasons for or against referring patients for DBS, except for the number of non‐specialists who agreed with referring a patient who had a “poor or absent response to levodopa” (71% vs. 16%, p < 0.001). Both groups indicated a need for more information concerning appropriate indications for DBS, adverse effects of surgery, and postoperative programming. Conclusions: Movement disorders specialists and non‐specialists were in general agreement towards the beneficial role of DBS in management of advanced PD except for whether to refer patients with poor or absent response to levodopa.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Ludy C. Shih MD</name></json:item><json:item><name>Daniel Tarsy MD</name><affiliations><json:string>Department of Neurology, National Parkinson Foundation Center of Excellence, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA, USA</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Deep brain stimulation</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>patient selection</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>prospective nonrandomized study</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>subthalamic nucleus</value></json:item></subject><articleId><json:string>NER350</json:string></articleId><language><json:string>eng</json:string></language><abstract>Objectives: Deep brain stimulation (DBS) for Parkinson's disease (PD) was approved by the Food and Drug Administration in 2002 and has demonstrated clinical benefit in advanced PD. Our aim was to assess attitudes of U.S. neurologists towards the role of DBS in management of advanced PD. Materials and Methods: We sent a 40‐item Internet‐based survey assessing opinions regarding the role of medical and surgical therapies in managing PD to 7722 neurologists in the American Medical Association Physician MasterFile data base. Results: The response rate was low (4.2%). In total, 78 of the 298 (26%) responders self‐identified as movement disorders specialists. Specialists and non‐specialists had differences on a number of medical strategies used to manage PD. There were no statistically significant differences in reasons for or against referring patients for DBS, except for the number of non‐specialists who agreed with referring a patient who had a “poor or absent response to levodopa” (71% vs. 16%, p > 0.001). Both groups indicated a need for more information concerning appropriate indications for DBS, adverse effects of surgery, and postoperative programming. Conclusions: Movement disorders specialists and non‐specialists were in general agreement towards the beneficial role of DBS in management of advanced PD except for whether to refer patients with poor or absent response to levodopa.</abstract><qualityIndicators><score>5.611</score><pdfVersion>1.3</pdfVersion><pdfPageSize>594 x 783 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>5</keywordCount><abstractCharCount>1409</abstractCharCount><pdfWordCount>3079</pdfWordCount><pdfCharCount>21185</pdfCharCount><pdfPageCount>6</pdfPageCount><abstractWordCount>211</abstractWordCount></qualityIndicators><title>Survey of U.S. Neurologists' Attitudes Towards Deep Brain Stimulation for Parkinson's Disease</title><genre><json:string>article</json:string></genre><host><volume>14</volume><publisherId><json:string>NER</json:string></publisherId><pages><total>6</total><last>213</last><first>208</first></pages><issn><json:string>1094-7159</json:string></issn><issue>3</issue><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1525-1403</json:string></eissn><title>Neuromodulation: Technology at the Neural Interface</title><doi><json:string>10.1111/(ISSN)1525-1403</json:string></doi></host><publicationDate>2011</publicationDate><copyrightDate>2011</copyrightDate><doi><json:string>10.1111/j.1525-1403.2011.00350.x</json:string></doi><id>1D9EE26C5DEE702DF5350DF8351846544D65813F</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/1D9EE26C5DEE702DF5350DF8351846544D65813F/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/1D9EE26C5DEE702DF5350DF8351846544D65813F/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/1D9EE26C5DEE702DF5350DF8351846544D65813F/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Survey of U.S. Neurologists' Attitudes Towards Deep Brain Stimulation for Parkinson's Disease</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Blackwell Publishing Inc</publisher><pubPlace>Malden, USA</pubPlace><availability><p>WILEY</p></availability><date>2011</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Survey of U.S. Neurologists' Attitudes Towards Deep Brain Stimulation for Parkinson's Disease</title><author><persName><forename type="first">Ludy C.</forename><surname>Shih</surname></persName><roleName type="degree">MD</roleName><note type="correspondence"><p>Correspondence: Ludy Shih, MD, Department of Neurology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Kirstein 228, Boston, MA 02215, USA. Email:</p></note></author><author><persName><forename type="first">Daniel</forename><surname>Tarsy</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, National Parkinson Foundation Center of Excellence, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA, USA</affiliation></author></analytic><monogr><title level="j">Neuromodulation: Technology at the Neural Interface</title><idno type="pISSN">1094-7159</idno><idno type="eISSN">1525-1403</idno><idno type="DOI">10.1111/(ISSN)1525-1403</idno><imprint><publisher>Blackwell Publishing Inc</publisher><pubPlace>Malden, USA</pubPlace><date type="published" when="2011-05"></date><biblScope unit="volume">14</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="208">208</biblScope><biblScope unit="page" to="213">213</biblScope></imprint></monogr><idno type="istex">1D9EE26C5DEE702DF5350DF8351846544D65813F</idno><idno type="DOI">10.1111/j.1525-1403.2011.00350.x</idno><idno type="ArticleID">NER350</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2011</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Objectives: Deep brain stimulation (DBS) for Parkinson's disease (PD) was approved by the Food and Drug Administration in 2002 and has demonstrated clinical benefit in advanced PD. Our aim was to assess attitudes of U.S. neurologists towards the role of DBS in management of advanced PD. Materials and Methods: We sent a 40‐item Internet‐based survey assessing opinions regarding the role of medical and surgical therapies in managing PD to 7722 neurologists in the American Medical Association Physician MasterFile data base. Results: The response rate was low (4.2%). In total, 78 of the 298 (26%) responders self‐identified as movement disorders specialists. Specialists and non‐specialists had differences on a number of medical strategies used to manage PD. There were no statistically significant differences in reasons for or against referring patients for DBS, except for the number of non‐specialists who agreed with referring a patient who had a “poor or absent response to levodopa” (71% vs. 16%, p < 0.001). Both groups indicated a need for more information concerning appropriate indications for DBS, adverse effects of surgery, and postoperative programming. Conclusions: Movement disorders specialists and non‐specialists were in general agreement towards the beneficial role of DBS in management of advanced PD except for whether to refer patients with poor or absent response to levodopa.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Deep brain stimulation</term></item><item><term>Parkinson's disease</term></item><item><term>patient selection</term></item><item><term>prospective nonrandomized study</term></item><item><term>subthalamic nucleus</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2011-05">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/1D9EE26C5DEE702DF5350DF8351846544D65813F/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Blackwell Publishing Inc</publisherName><publisherLoc>Malden, USA</publisherLoc></publisherInfo><doi origin="wiley" registered="yes">10.1111/(ISSN)1525-1403</doi><issn type="print">1094-7159</issn><issn type="electronic">1525-1403</issn><idGroup><id type="product" value="NER"></id><id type="publisherDivision" value="ST"></id></idGroup><titleGroup><title type="main" sort="NEUROMODULATION TECHNOLOGY AT THE NEURAL INTERFACE">Neuromodulation: Technology at the Neural Interface</title></titleGroup></publicationMeta><publicationMeta level="part" position="05103"><doi origin="wiley">10.1111/ner.2011.14.issue-3</doi><numberingGroup><numbering type="journalVolume" number="14">14</numbering><numbering type="journalIssue" number="3">3</numbering></numberingGroup><coverDate startDate="2011-05">May/June 2011</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="3" status="forIssue"><doi origin="wiley">10.1111/j.1525-1403.2011.00350.x</doi><idGroup><id type="unit" value="NER350"></id></idGroup><countGroup><count type="pageTotal" number="6"></count></countGroup><titleGroup><title type="tocHeading1">Brain</title><title type="tocHeading2">Prospective Nonrandomized Study</title></titleGroup><copyright>© 2011 International Neuromodulation Society</copyright><eventGroup><event type="xmlConverted" agent="Converter:BPG_TO_WML3G version:2.5.2 mode:FullText" date="2011-07-19"></event><event type="publishedOnlineEarlyUnpaginated" date="2011-04-01"></event><event type="publishedOnlineFinalForm" date="2011-06-01"></event><event type="firstOnline" date="2011-04-01"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:4.0.1" date="2014-03-19"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst" number="208">208</numbering><numbering type="pageLast" number="213">213</numbering></numberingGroup><correspondenceTo>Ludy Shih, MD, Department of Neurology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Kirstein 228, Boston, MA 02215, USA. Email: <email>lshih@bidmc.harvard.edu</email></correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:NER.NER350.pdf"></link></linkGroup></publicationMeta><contentMeta><unparsedEditorialHistory>Received: December 21, 2010 Accepted: January 26, 2011</unparsedEditorialHistory><countGroup><count type="figureTotal" number="6"></count><count type="tableTotal" number="2"></count><count type="formulaTotal" number="0"></count><count type="referenceTotal" number="9"></count><count type="wordTotal" number="2300"></count><count type="linksPubMed" number="0"></count><count type="linksCrossRef" number="0"></count></countGroup><titleGroup><title type="main">Survey of U.S. Neurologists' Attitudes Towards Deep Brain Stimulation for Parkinson's Disease</title><title type="shortAuthors">SHIH & TARSY</title><title type="short">SURVEY OF ATTITUDES TOWARDS DBS FOR PD</title></titleGroup><creators><creator creatorRole="author" xml:id="cr1" corresponding="yes"><personName><givenNames>Ludy C.</givenNames><familyName>Shih</familyName><degrees>MD</degrees></personName></creator><creator creatorRole="author" xml:id="cr2" affiliationRef="#aff-1-1"><personName><givenNames>Daniel</givenNames><familyName>Tarsy</familyName><degrees>MD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="aff-1-1" countryCode="US"><unparsedAffiliation>Department of Neurology, National Parkinson Foundation Center of Excellence, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA, USA</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en"><keyword xml:id="k1">Deep brain stimulation</keyword><keyword xml:id="k2">Parkinson's disease</keyword><keyword xml:id="k3">patient selection</keyword><keyword xml:id="k4">prospective nonrandomized study</keyword><keyword xml:id="k5">subthalamic nucleus</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><p><b>Objectives: </b> Deep brain stimulation (DBS) for Parkinson's disease (PD) was approved by the Food and Drug Administration in 2002 and has demonstrated clinical benefit in advanced PD. Our aim was to assess attitudes of U.S. neurologists towards the role of DBS in management of advanced PD.</p><p><b>Materials and Methods: </b> We sent a 40‐item Internet‐based survey assessing opinions regarding the role of medical and surgical therapies in managing PD to 7722 neurologists in the American Medical Association Physician MasterFile data base.</p><p><b>Results: </b> The response rate was low (4.2%). In total, 78 of the 298 (26%) responders self‐identified as movement disorders specialists. Specialists and non‐specialists had differences on a number of medical strategies used to manage PD. There were no statistically significant differences in reasons for or against referring patients for DBS, except for the number of non‐specialists who agreed with referring a patient who had a “poor or absent response to levodopa” (71% vs. 16%, <i>p</i> < 0.001). Both groups indicated a need for more information concerning appropriate indications for DBS, adverse effects of surgery, and postoperative programming.</p><p><b>Conclusions: </b> Movement disorders specialists and non‐specialists were in general agreement towards the beneficial role of DBS in management of advanced PD except for whether to refer patients with poor or absent response to levodopa.</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn2"><p>Disclaimers: None to make.</p></note><note xml:id="fn3"><p>For more information on author guidelines, an explanation of our peer review process, and conflict of interest informed consent policies, please go to <url href="http://www.wiley.com/bw/submit.asp?ref=1094-7159&site=1">http://www.wiley.com/bw/submit.asp?ref=1094‐7159&site=1</url></p></note><note xml:id="fn4"><p><b>Conflict of Interest:</b> Ludy Shih received support from the Clinical Investigator Training Program: Beth Israel Deaconess Medical Center—Harvard/MIT Health Sciences and Technology, in collaboration with Pfizer Inc. and Merck & Co. Daniel Tarsy has received research funding from Schwarz Pharma and patient education grants from Teva Neurosciences and Boehringer Ingelheim. He has also received consulting fees from Eisai Neuroscience. Medtronic funded the costs associated with administering the survey and data collection. The authors did not receive any payments for conducting the study. Data collection and results interpretation were solely performed by the authors.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Survey of U.S. Neurologists' Attitudes Towards Deep Brain Stimulation for Parkinson's Disease</title></titleInfo><titleInfo type="abbreviated"><title>SURVEY OF ATTITUDES TOWARDS DBS FOR PD</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Survey of U.S. Neurologists' Attitudes Towards Deep Brain Stimulation for Parkinson's Disease</title></titleInfo><name type="personal"><namePart type="given">Ludy C.</namePart><namePart type="family">Shih</namePart><namePart type="termsOfAddress">MD</namePart><description>Correspondence: Ludy Shih, MD, Department of Neurology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Kirstein 228, Boston, MA 02215, USA. Email: </description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Daniel</namePart><namePart type="family">Tarsy</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, National Parkinson Foundation Center of Excellence, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Blackwell Publishing Inc</publisher><place><placeTerm type="text">Malden, USA</placeTerm></place><dateIssued encoding="w3cdtf">2011-05</dateIssued><edition>Received: December 21, 2010 Accepted: January 26, 2011</edition><copyrightDate encoding="w3cdtf">2011</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">6</extent><extent unit="tables">2</extent><extent unit="references">9</extent><extent unit="words">2300</extent></physicalDescription><abstract lang="en">Objectives: Deep brain stimulation (DBS) for Parkinson's disease (PD) was approved by the Food and Drug Administration in 2002 and has demonstrated clinical benefit in advanced PD. Our aim was to assess attitudes of U.S. neurologists towards the role of DBS in management of advanced PD. Materials and Methods: We sent a 40‐item Internet‐based survey assessing opinions regarding the role of medical and surgical therapies in managing PD to 7722 neurologists in the American Medical Association Physician MasterFile data base. Results: The response rate was low (4.2%). In total, 78 of the 298 (26%) responders self‐identified as movement disorders specialists. Specialists and non‐specialists had differences on a number of medical strategies used to manage PD. There were no statistically significant differences in reasons for or against referring patients for DBS, except for the number of non‐specialists who agreed with referring a patient who had a “poor or absent response to levodopa” (71% vs. 16%, p < 0.001). Both groups indicated a need for more information concerning appropriate indications for DBS, adverse effects of surgery, and postoperative programming. Conclusions: Movement disorders specialists and non‐specialists were in general agreement towards the beneficial role of DBS in management of advanced PD except for whether to refer patients with poor or absent response to levodopa.</abstract><subject lang="en"><genre>Keywords</genre><topic>Deep brain stimulation</topic><topic>Parkinson's disease</topic><topic>patient selection</topic><topic>prospective nonrandomized study</topic><topic>subthalamic nucleus</topic></subject><relatedItem type="host"><titleInfo><title>Neuromodulation: Technology at the Neural Interface</title></titleInfo><genre type="Journal">journal</genre><identifier type="ISSN">1094-7159</identifier><identifier type="eISSN">1525-1403</identifier><identifier type="DOI">10.1111/(ISSN)1525-1403</identifier><identifier type="PublisherID">NER</identifier><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>14</number></detail><detail type="issue"><caption>no.</caption><number>3</number></detail><extent unit="pages"><start>208</start><end>213</end><total>6</total></extent></part></relatedItem><identifier type="istex">1D9EE26C5DEE702DF5350DF8351846544D65813F</identifier><identifier type="DOI">10.1111/j.1525-1403.2011.00350.x</identifier><identifier type="ArticleID">NER350</identifier><accessCondition type="use and reproduction" contentType="copyright">© 2011 International Neuromodulation Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Blackwell Publishing Inc</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001724 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001724 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:1D9EE26C5DEE702DF5350DF8351846544D65813F
|texte= Survey of U.S. Neurologists' Attitudes Towards Deep Brain Stimulation for Parkinson's Disease
}}
| This area was generated with Dilib version V0.6.23. |  |